Hematologic Malignancy
Nodular Lymphocyte Predominant B-Cell Lymphoma
CI-CAN-00001280NLPBL · NLPHLExplore in graph →
Hematologic2 active trials
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001280NLPBL · NLPHLExplore in graph →
Clinical trials
16 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00288067 | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Oct 6, 2014source: clinicaltrials